Free tool
FAERS Monitor: Indomethacin
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022536 or its brand name (Indomethacin, Indomethacin). Reports on generic versions are filed under their own applications.
Reports
11,101
Serious
9,017
81% of reports
Hospitalization
3,780
Death reported
1,293
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective1,316
- fatigue1,063
- headache978
- off label use968
- arthralgia957
- pain851
- nausea840
- diarrhoea837
- dizziness805
- vomiting689
- dyspnoea681
- asthenia599
- pruritus593
- malaise585
- pyrexia574
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 218 |
| 2005 | 264 |
| 2006 | 278 |
| 2007 | 257 |
| 2008 | 266 |
| 2009 | 307 |
| 2010 | 270 |
| 2011 | 371 |
| 2012 | 458 |
| 2013 | 314 |
| 2014 | 280 |
| 2015 | 385 |
| 2016 | 540 |
| 2017 | 466 |
| 2018 | 649 |
| 2019 | 707 |
| 2020 | 583 |
| 2021 | 716 |
| 2022 | 981 |
| 2023 | 843 |
| 2024 | 873 |
| 2025 | 732 |
| 2026 | 342 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,043,058 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| arthralgiaSignal | 957 | 4.4 | 4.1 | 2,527 |
| pyrexiaSignal | 574 | 3.1 | 2.9 | 851 |
| dizzinessSignal | 805 | 3.1 | 2.9 | 1,140 |
| astheniaSignal | 599 | 3.0 | 2.8 | 822 |
| headacheSignal | 978 | 3.0 | 2.8 | 1,303 |
| pruritusSignal | 593 | 2.9 | 2.7 | 763 |
| vomitingSignal | 689 | 2.8 | 2.6 | 800 |
| painSignal | 851 | 2.6 | 2.5 | 880 |
| fatigueSignal | 1,063 | 2.6 | 2.4 | 1,074 |
| malaiseSignal | 585 | 2.5 | 2.3 | 550 |
| diarrhoeaSignal | 837 | 2.5 | 2.3 | 745 |
| dyspnoeaSignal | 681 | 2.3 | 2.1 | 501 |
| off label useSignal | 968 | 2.1 | 2.0 | 577 |
| nauseaSignal | 840 | 2.0 | 1.9 | 443 |
| drug ineffective | 1,316 | 1.9 | 1.8 | 590 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.